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Abstract 
Baseline beta-cell mass is established during the early postnatal period when 
beta cells expand. Here, we show that heterozygous ablation of Insm1 
decreases baseline beta-cell mass and subsequently impairs glucose 
tolerance. When exposed to a high-fat diet or on an ob/ob background, 
glucose intolerance was more severe in Insm1+/lacZ mice compared to 
Insm1+/+ mice, although no further decrease in the beta-cell mass was 
detected. In islets of early postnatal Insm1+/lacZ mice, cell cycle was prolonged 
in beta cells due to downregulation of the cell cycle gene Ccnd1. Although 
Insm1 had a low affinity for the Ccnd1 promoter compared to other binding 
sites, binding affinity was strongly dependent on Insm1 levels. We observed 
dramatically decreased binding of Insm1 to the Ccnd1 promoter after 
downregulation of Insm1 expression. Furthermore, downregulation of Ccnd1 
resulted in a prolonged cell cycle and overexpression of Ccnd1 rescued cell 
cycle abnormalities observed in Insm1-deficient beta cells. We conclude that 
decreases in Insm1 interfere with beta-cell specification during the early 
postnatal period and impair glucose homeostasis during metabolic stress in 
adults. Insm1 levels are therefore a factor that can influence the development 
of diabetes. 
Introduction 
Pancreatic beta-cell mass is regulated both during development and in the 
adult. Lineage tracing in animals indicates that embryonic beta cells mainly 
differentiate from pancreatic progenitor cells [1], while postnatal increases in 
beta-cell mass arise through self-renewal [2, 3]. Beta-cell replication slows 
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considerably in adults, although variations in insulin demand can lead to 
adaptive changes in beta-cell mass [4]. Sufficient beta-cell mass is essential 
for normal regulation of blood glucose levels. Loss of beta-cell mass by an 
immune attack or metabolic stressors results in type 1 and type 2 diabetes, 
respectively. In addition, although beta-cell mass varies in individuals, low 
beta-cell mass is a risk factor for prediabetes and diabetes [5]. At least two 
factors contribute to total beta-cell mass: replication capacity and baseline 
beta-cell mass. The replication rate of adult beta cells is low, and massive 
efforts have been made to restore diabetic beta-cell loss by enhancing beta-
cell replication. In contrast, the establishment of the baseline beta-cell mass is 
not well investigated, and it is not yet fully understood how postnatal beta-cell 
expansion varies in different individuals. 
The baseline beta-cell mass is established in the early postnatal period both 
in mice and humans [2, 6-8]. Recent identified factors that modulate the 
postnatal beta-cell expansion regulate the metabolic pathways or the cell 
cycle [9, 10, 11]. The cyclin genes Ccnd1 and Ccnd2 are essential for 
postnatal beta-cell growth and regulate the progression through G1 through 
interaction with Cdk4 [12-14]. Heterozygous mutations in Ccnd1 combined 
with complete knockout of Ccnd2 has dose-dependent effects on beta-cell 
mass [14]. Cell cycle inhibitors are another group of essential regulators in the 
postnatal beta-cell mass expansion. p16INK4a is a beta-cell replication inhibitor 
specifically expressed in aging beta cells. Therefore, although mutation of 
p16INK4a has no effect on the early postnatal beta-cell mass, overexpression of 
p16INK4a decreases postnatal beta-cell mass [15]. p21, p27 and p57 regulate 
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the cell cycle in embryonic beta cells [16, 17] as well as postnatal pancreatic 
beta-cell proliferation [18].  
Insm1 encodes a zinc finger protein that is essential for the development and 
function of mature beta cells. Null mutation of Insm1 interferes with the 
formation of insulin positive beta cells [19, 20], whereas deletion of Insm1 in 
adult beta cells leads to loss of mature beta-cell function [21]. Here, we show 
that Insm1 haploinsufficiency impairs the early postnatal beta-cell expansion, 
resulting in decreased baseline beta-cell mass and impaired glucose 
tolerance. Mechanistically, the decreased dosage of Insm1 prolongs the cell 
cycle in part by targeting Ccnd1. Insm1 binds to the Ccnd1 locus with low 
affinity in beta cells and binding is dramatically lost upon downregulation of 
Insm1. Our data demonstrate that Insm1 regulates postnatal baseline beta-
cell mass in a dose-dependent manner, indicating that decreased Insm1 
expression is a potential risk factor for diabetes. 
Research Design and Methods 
Animals and genotyping  
The Insm1lacZ allele was reported previously [19]. Male animals were used for 
all experiments. Wild-type littermates were used as controls. A high-fat diet 
treatment was started at 3 months of age, and glucose tolerance and the 
beta-cell mass was measured after 10-months on the high-fat diet. Ob/ob 
mice were analyzed at 13 months of age. All animal experiments were 
approved by the Institutional Animal Care and Use Committee of Jinan 
University. 
Blood glucose levels, insulin levels and beta-cell mass  
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Blood glucose and blood insulin measurements were performed as previously 
described [21]. Briefly, blood glucose levels from each animal were 
determined from at least three independent measurements on different days. 
Blood insulin levels from each animal were determined from average values 
obtained from at least two independent measurements on different days. For 
glucose tolerance and insulin secretion tests, glucose was injected 
intraperitoneally (2 g/kg body weight, unless otherwise indicated). Insulin and 
glucagon ELISA kits were used to detect insulin and glucagon levels in the 
blood (90080, Crystal Chem, Downers Grove, USA; DGCG0, Quantikine® 
ELISA, R&D Systems, Inc., MN, USA) 
Beta-cell mass was determined as previously described [21]. In short, each 
pancreas was evenly flattened and fixed in 4% PFA for 3 hours, embedded in 
paraffin, and then sectioned at 8 µm thickness. For beta-cell mass analysis, 
we collected sections every 10th sections in 2-, 7- and 14-day old animals, and 
every 20th sections in 2-month, 13-month, HFD and ob mice; that is, 
approximately 8-10 pancreatic sections for each animal were used. Beta-cell 
area was identified by immunofluorescence using anti-insulin antibodies.  The 
total area of the pancreas, insulin-positive area and pancreas weight were 
used to calculate beta-cell mass: beta-cell mass (mg/pancreas) = whole 
pancreas weight (mg) * insulin positive area/pancreas area. Image J software 
was used to quantify the areas of pancreas and beta-cell. 
Immunofluorescence and Western blot 
Immunofluorescence and Western blots were performed as described [21]. 
Fluorescence was imaged on a Zeiss LSM 700 confocal microscopy and 
processed using Adobe Photoshop software. Anti-Insm1, anti-insulin, anti-
Page 5 of 42 Diabetes
 6
Glut2, anti-BrdU and anti-ActB antibodies were used as previously described 
[21], and anti-Ccnd1 antibody was purchased from Abcam (ab-134175) and 
Santa Cruz (sc-753). Anti-Ki67 antibody was purchased from Dako (M7249) 
and Abcam (ab15580). Anti-p16 (ab51243, Abcam), anti-p21 (ab109199, 
Abcam), anti-p27 (ab92741, Abcam), anti-p57 (ab75974, Abcam), anti-CcnE1 
(20808S, CST) and anti-CcnA2 (ab181591, Abcam) antibodies were used for 
Western blotting. Secondary antibodies (Jackson ImmunoResearch) coupled 
to Cy3, Cy2, Cy5 (for immunofluorescence) or horseradish peroxidase (for 
Western blot) were used. 
Pancreatic islets isolation and insulin secretion assay 
Pancreatic islets were isolated as previously described [21]. The assay was 
performed by incubating islets for 30 min in secretion buffer containing 3.3 
mM or 16.7 mM glucose with washing and pre-incubation steps between and 
before the assay [21]. Released insulin was quantified using an ELISA kit (80-
INSMSH, ALPCO, NH, USA) as described [21]. 
qRT-PCR analysis 
Freshly isolated islets or cultured SJb cells were lysed, and total RNA was 
isolated using Trizol reagent (Invitrogen). For qRT-PCR analysis, cDNA from 
each animal was synthetized using PrimeScript™ RT reagent Kit with gDNA 
Eraser (TakaRa, China) and analyzed using SYBR® Fast qPCR Mix (TaKaRa, 
China) on CFX96 RT-PCR system (Bio-Rad). Expression levels were 
determined using the 2-∆∆Ct method. ActB was used as internal standard, and 
the results were displayed as the proportion of wild-type controls. Primers 
used for quantitative analysis are listed in Supplemental Table S1. 
ChIP-PCR 
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For ChIP-PCR, we used isolated pancreatic islets or SJb beta-cell line. Anti-
Insm1 antibody was used for ChIP-PCR as described in our previous study 
[21]. The PCR primers used for chromatin analysis are shown in 
Supplemental Table S1.  
siRNA knockdown 
siRNAs against Insm1 and Ccnd1 mRNAs were delivered by electroporation 
with the Amaxa Nucleofector using the Amaxa kit V and program G-16, 
according to the protocols provided by the kits. Mouse Insm1 and 
nontargeting control siRNAs were purchased from Dharmacon (J-049233 -
09/-11/-12 for Insm1 and D-001810-10 for control). Mouse Ccnd1 siRNAs 
were purchased from Ambion (s63513, s201129). 
PI staining and flow cytometer analysis 
Alcohol fixed SJb cells were washed with PBS and incubated with PBS 
containing 0.1% Triton-X-100, 3 mg/mL DNase-free RNase (EN0531, Thermo 
Fisher) and 20 µg/µL propidium iodide (Biofroxx, Germany) for 15 min at 
37°C. Cells were directly analyzed on an LSR Fortessa analyzer (Beckton 
Dickenson, Franklin Lakes, USA). Cell cycle distributions were calculated 
using the Dean-Jett model in FloJo X10.0.7r2. A representative result from 4 




Impaired glucose tolerance and beta-cell mass in Insm1 heterozygote 
mice 
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To investigate the effects of Insm1 gene dosage on beta-cell function, we 
used Insm1+/lacZ mice that harbor one intact Insm1 allele and one mutant allele 
in which lacZ replaces the Insm1 coding sequence [19]. In Insm1+/lacZ islets, 
Insm1 protein levels were lower at 2-months or 2-weeks of age (Fig. 1A, Fig. 
S1). Compared to Insm1+/+ mice, blood glucose levels were significantly 
higher in Insm1+/lacZ mice on a random feeding schedule, while the fasting 
blood glucose levels were comparable (Fig. 1B). Insm1+/lacZ mice were 
glucose intolerant (Fig. 1C) and displayed defects in glucose stimulated 
insulin secretion (Fig. 1D). Although the blood glucagon levels were 
comparable in Insm1+/lacZ and Insm1+/+ mice in both fasted and randomly fed 
conditions (Fig. 1E), the proportions of glucagon-producing alpha cells and 
other endocrine cell types were not altered (Fig. S2). Moreover, there was no 
change in peripheral insulin sensitivity in Insm1+/lacZ mice using an insulin 
tolerance test (Fig. 1F). We isolated islets and performed glucose-stimulated 
insulin secretion ex vivo. We observed comparable levels of insulin secretion 
in islets from both genotypes at low and high glucose concentrations (Fig. 
1G). In Insm1+/lacZ mice, we observed reduced insulin secretion in vivo but 
normal secretion in isolated islets, indicating insufficient beta-cell mass. 
Indeed, we observed that the beta-cell mass in Insm1+/lacZ mice was 70.9% of 
that of Insm1+/+ mice at 2-months (P2 M) (Fig. 1H). This decrease in beta-cell 
mass was not caused by differences in beta-cell size, as comparable cell 
sizes were observed in wide-type and Insm1+/lacZ mice (Fig. S3). 
To further dissect the time course of the deficits, we measured beta-cell mass 
in postnatal 2-day (P2), 7-day (P7), 14-day (P14) and 13-month (P13M) (Fig. 
1H). We observed comparable beta-cell mass between newborn (P2) 
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Insm1+/+ and Insm1+/lacZ mice. A small, but not significant, decrease in beta-
cell mass was detected at P7 in Insm1+/lacZ mice. Significant decreases in 
beta-cell mass were detected at P14, when the beta-cell mass of Insm1+/lacZ 
mice was 77.6% of that observed in Insm1+/+ mice. A further decrease in beta-
cell mass was detected at P2M in Insm1+/lacZ mice (70.9% at P2M vs P77.6% 
at P14, p=0.0058). However, there were no further differences in beta-cell 
mass between Insm1+/lacZ and Insm1+/+ mice after P2M, as beta-cell mass 
remained approximately 70.9% at P2M and 65.9% at P13M (p=0.7798) (Fig. 
1H). These data indicated that the impaired beta-cell expansion occurs in the 
postnatal period between 7-days and 2-months.  
 
Delayed cell cycle in beta-cell of Insm1 heterozygotes mice 
Because we first observed significant changes in beta-cell mass at P14, we 
used this time point to analyze in vivo experiments, unless otherwise 
indicated. Increased TUNEL staining in Insm1+/lacZ beta cells were detected at 
both P7 and P14 but not at P2 (Fig. 2A), while proliferation, indicated by the 
presence of Ki67, was comparable (Fig. 2B). Thus, increased apoptosis 
contributes to the low beta-cell mass in Insm1+/lacZ mice. However, we noticed 
that the apoptosis rate was much lower than the rate of proliferation (i.e., 1.5 
apoptotic cells per 1000 insulin positive cells versus 180 proliferated cells per 
1000 insulin positive cells at P7) (Fig. 2A, B), suggesting that apoptosis might 
not be a major contributor to the decrease in beta-cell mass.  
We investigated cell cycle length using BrdU pulse-chase combined with Ki67 
staining in P14 Insm1+/lacZ and Insm1+/+ mice. A single pulse of BrdU was 
administered to mice followed by a 23-hour chase period, the approximate 
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amount of time needed to complete one cycle of cell division [22]. BrdU 
labeling was retained by the cells within the cell cycle as well as those that 
had reached a postmitotic state, while Ki67 only labeled the cells in the cell 
cycle. Thus, BrdU+Ki67- cells had exited the cell cycle while BrdU+Ki67+ cells 
had not yet completed the cell cycle (Fig. 2C). We found significantly 
decreased numbers of BrdU+Ki67- cells and increased numbers of BrdU+Ki67+ 
cells in Insm1+/lacZ mice (Fig. 2D, E), indicating that cell cycle length in 
Insm1+/lacZ beta cells was prolonged. This prolonged cell cycle could be 
repeatedly detected at 3 weeks but not at 10 weeks in Insm1+/lacZ mice (Fig. 
S4A). We further counted cell numbers in different phases of the cell cycle 
using propidium iodide (PI) staining and flow cytometry analysis. Knockdown 
of Insm1 in SJb cells, a previously described pancreatic beta-cell line that 
retains many of the in vivo characteristics of beta cells [21], resulted in a 
small, but significant increase, in cells in G0/G1 (Fig. 3A). Thus, 
haploinsufficiency of Insm1 in beta cells delays the cell cycle.  
Because we observed delayed cell cycle and increased apoptosis in 
Insm1+/lacZ mice, we asked whether abnormalities in cell cycle caused cell 
death. We performed TUNEL staining followed by immunofluorescence 
analysis using Ki67 staining. However, we did not detect any costaining of 
TUNEL and Ki67 in over 1000 Ki67+ cells per animal at postnatal day 14 
(data not shown). Although decreases in Insm1 led to a longer cell cycle, 
proliferating cells did not directly enter cell death in Insm1+/lacZ islets. 
 
Ccnd1 expression levels are downregulated in islets of Insm1 
heterozygotes mice  
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The cell cycle is marked and regulated by numerous cyclin genes [23, 24]. We 
investigated the expression of cyclin, cyclin kinase and cyclin kinase inhibitor 
genes. We found that of the G1/S phase cyclins, only Ccnd1 was 
downregulated in P14 Insm1+/lacZ islets (Fig. 3B). Ccnd1 was further 
downregulated in SJb cells treated with Insm1 siRNA and in P7 Insm1+/lacZ 
islets (Fig. S4B, C). We further verified decreases in Ccnd1 protein but not 
other cell cycle regulators in islets isolated from P14 Insm1+/lacZ mice (Fig. 3C 
and Fig. S5A). Because Ccnd1 expression was consistently decreased in 
both early and postnatal Insm1+/lacZ islets and Insm1 deficient SJb cells, we 
investigated the regulation of cell cycle length by Ccnd1. 
Knockdown of Insm1 by siRNA in SJb cells resulted in fewer BrdU+Ki67- cells 
and an increase in BrdU+Ki67+ cells (Fig. 3D). Similar changes were observed 
after knockdown of Ccnd1 expression (Fig. 3D). Next, we overexpressed 
Ccnd1 in SJb cells treated with Insm1 siRNA. Significantly increased numbers 
of BrdU+Ki67- cells and decreased numbers of Brdu+Ki67+ cells were 
observed, demonstrating that the downregulation of Insm1 expression can be 
rescued by overexpressing Ccnd1 (Fig. 3D). PI labeling and flow cytometry 
cell cycle analysis showed that significant increases in cell number were 
detected in the G0/G1 phase in Insm1 or Ccnd1 knockdown cells, while 
overexpression of Ccnd1 in Insm1 knockdown SJb cells rescued the 
increasing of G0/G1 phase cell numbers (Fig. 3A). In summary, Ccnd1 is a 
downstream target of Insm1 and controls cell cycle length. 
In our previous study, we observed downregulation of many metabolic genes 
and transcription factors in islets after conditional ablation of Insm1 [21], 
leading us to investigate the expression of these genes in Insm1+/lacZ islets. 
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We detected downregulation of Glut2 but no change in Pcx, Hk1, Pdx1 or 
MafA (Fig. 4A,B, Fig. 5SB), suggesting that Insm1 target gene Glut2 is 
regulated in a dose-dependent manner by Insm1. 
 
Binding of Insm1 on low affinity targets depends on Insm1 dose  
To investigate the mechanisms of Insm1-dependent regulation of Ccnd1, we 
analyzed Insm1 ChIP-seq data [21]. We observed binding of Insm1 on both 
the promoter and intron regions of Ccnd1 (Fig. 5A). The number of reads on 
the Ccnd1 gene observed in the ChIP-seq data set was lower than that 
detected in other Insm1 binding genes, such as the Pdx1 and Hk1 genes. 
However, Insm1 broadly binds to Pdx1, and these binding sites belong to a 
cluster of enhancers called superenhancers [25, 26], which is therefore high-
affinity binding (Fig. 5A). To determine how levels of Insm1 influenced binding 
to chromatin, we performed ChIP-PCR on control and Insm1 siRNA-treated 
SJb cells. Knockdown of Insm1 reduced Insm1 protein levels (Fig. 5B, left), 
and binding of Insm1 on Hk1, Pdx1 and Glut2 decreased by 1.4-, 1.7- and 
5.7-fold, respectively. The decrease of Insm1 binding to the promoter and 
intron regions of Ccnd1 was more pronounced, where an 8.8- and 10.3-fold 
decrease, respectively, was observed after Insm1 knockdown (Fig. 5B right). 
We further verified the decreased binding of Insm1 on the Ccnd1 and Glut2 
loci in P14 Insm1+/lacZ islets (Fig. 5C). These data indicated that the low affinity 
binding sites were prone to losing Insm1 binding in response to decreases in 
Insm1. In summary, Insm1 binds to Ccnd1 and Glut2 with relatively low 
affinity, and this binding is sensitive to changes in levels of Insm1. 
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Metabolic stress aggravates glucose intolerance in Insm1 heterozygotes 
mice 
To investigate the effect of Insm1 haploinsufficiency on the glycemic 
phenotype after metabolic stress, we introduced the Insm1+/lacZ allele into the 
ob/ob background. We performed glucose tolerance tests (glucose was 
administered at 0.5 g/kg body weight) and observed severe glucose 
intolerance (Fig. 6A). The glucose tolerance of Insm1+/lacZ mice in the ob/ob 
background was much lower than observed in age matched wild-type animals 
(Fig. 6B). Similarly, Insm1+/lacZ mice on a high-fat diet (HFD) showed further 
decreases in glucose tolerance (Fig. 6C). Although the fasted blood glucose 
levels in Insm1+/lacZ mice were comparable to Insm1+/+ mice on an HFD, these 
levels increased in an ob/ob background (Fig. 6D). Random blood glucose 
levels were consistently higher in Insm1+/lacZ mice either on an HFD or in an 
ob/ob background (Fig. 6E).  
To investigate whether the beta-cell mass of Insm1+/lacZ mice is further 
decreased during metabolic stress, we measured the beta-cell mass after 
HFD treatment or in an ob/ob background. In Insm1+/+ animals, beta-cell mass 
increased to 7.96 mg and 11.92 mg, while the mass in Insm1+/lacZ mice was 
5.22 mg and 7.56 mg in HFD treated or ob/ob background animals, 
respectively (Fig. 6F). The ratio of beta-cell mass (Insm1+/lacZ vs Insm1+/+) was 
similar in animals on a high-fat diet (65.6%) or in an ob/ob background 
(63.5%) compared to age matched animals on a normal diet (65.9%; unpaired 
t-test, p=0.94 for HFD and p=0.84 for ob/ob). We investigated the expression 
of Ccnd1 and Glut2 in islets of 13-month-old mice and found comparable 
expression of Ccnd1 but decreased Glut2 expression in Insm1+/lacZ compared 
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to Insm1+/+ mice (Fig. 6G). We performed ChIP-PCR in the aging islets; we 
found comparable Insm1 binding to the Ccnd1 locus but lower binding to the 
Glut2 locus in Insm1+/lacZ mice (Fig. 6H). Together, our data indicate that the 
Insm1 dosage is particularly important for Ccnd1 expression and the 
establishment of beta-cell mass specifically at early postnatal stages. Thus, 
decreases in beta-cell mass and Glut2 expression in Insm1+/lacZ animals 
contribute to impaired glucose handling during metabolic stress.  
 
Discussion  
Ccnd1 gene is regulated at the transcriptional and translational levels [27, 28, 
29]. We found that Ccnd1 transcription is dependent on Insm1 dosage and 
the protein level is also decreased in beta cells of Insm+/lacZ mice. Thus, Insm1 
can transcriptionally regulate the cell cycle by targeting Ccnd1. Our previous 
work elucidated that the protein complex Insm1/NeuroD1/FoxA2 binds with 
high affinity to pancreatic beta-cell genes that play an essential role in 
maintaining mature beta-cell function [21]. Here, we identified that Insm1 
dosage mainly affects the low affinity binding sites, i.e., the Ccnd1 locus. 
Thus, we elucidated a novel mechanism of Insm1 function in pancreatic beta 
cells.  
 
We show here that the decreased baseline beta-cell mass established at early 
postnatal stages in the Insm1+/lacZ mice was unchanged in the adult with or 
without metabolic stress. Thus, at least in the Insm1+/lacZ mice, the baseline 
beta-cell mass established in the early postnatal period determined the 
functional beta cells in the adult; it will be interesting to see whether this is a 
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general phenomenon. In addition, we observed that Ccnd1 expression was 
not downregulated in the islets of the adult Insm1+/lacZ mice. This suggests 
that Insm1 might not be involved in regulating Ccnd1 expression in adult beta 
cells, or that one allele of Insm1 is sufficient to support the very low 
proliferation rate and Ccnd1 expression in adult beta cells. We did not 
observe decreases in beta-cell mass in the newborn Insm1+/lacZ mice, 
indicating that Insm1 dosage has little effect on beta-cell development. 
Prenatal beta cells differentiate from stem/progenitor cells [1], while the 
postnatal beta-cell expansion arises from the self-duplication of beta cells [3]. 
There are different scenarios to describe regulation of beta-cell mass in the 
two different developmental stages. For instance, Nkx6.1 is required for 
postnatal, but not prenatal, beta-cell mass expansion [9]; Ccnd1, identified as 
a target of Insm1 in our work, does not contribute to prenatal beta-cell growth 
[13, 14]. We found that Insm1 dosage regulates Glut2 expression. Glut2, an 
gene essential for glucose sensing and metabolism, was markedly reduced in 
diabetic animals [30, 31, 32]. We observed a decrease of approximately 40% 
in Glut2 expression in the islets of Insm1+/lacZ mice, which could contribute to 
the impaired glucose handling under physiological or metabolically stressed 
conditions.  
 
We showed that changes in Insm1 expression only regulate a few Insm1 
targets, which were identified in Insm1 null mutation (as showed in Fig. 3B 
and Fig. 4A). The cell cycle genes Cdkn1c (p57), Cdkn1b (p27) and Ccnd1 
were downregulated in Insm1 null mutants [20, 21], but only Ccnd1 was 
downregulated in Insm1 heterozygotes (Fig. 3B). The transcription factors and 
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metabolic genes Pdx1, MafA, Glut2, Hk1 and Pcx were downregulated in 
Insm1 mutants [21]. However, only Glut2 was downregulated in Insm1 
heterozygotes (Fig. 4A). We found that the binding affinity of Insm1 to 
chromatin varied depending on the locus. Low affinity binding sites were more 
susceptible to decreases in Insm1 levels and therefore to be potentially 
affected by Insm1 dosage deficiency. Loci with no affinity or high affinity for 
did not show dysregulation of the related genes in Insm1+/lacZ islets (Fig. S5C 
and Fig. 3B; Fig. 5A and Fig. 4A). Thus, only genes that have relatively low 
Insm1 binding affinity are potentially regulated by Insm1 in a dose-dependent 
manner. 
 
Osipovich et al. observed increased Ccnd1 expression and 7-fold decreased 
proliferation in embryonic pancreatic beta cells in the absence of Insm1 [20], 
as well as a slight increase in proliferation and decrease in Ccnd1 expression 
in mature Insm1 deficient beta cells [21]. These studies investigated Insm1 
function at embryonic or adult stages in the absence of Insm1 and did not 
study dose-dependent effects. Embryonic loss of Insm1 results in severe 
developmental defects (loss of beta-cell development and no insulin 
production [19, 33]), and conditional loss of Insm1 in adult islets causes 
functional defects (continuous leak of insulin). However, Ccnd1 expression is 
not only directly regulated by Insm1 but also indirectly regulated by these 
defects. In fact, insulin and glucose are essential regulators of beta-cell 
proliferation [34,35]. Severe developmental defects, abnormal blood insulin 
and glucose levels, or higher numbers of and/or more intense dysregulated 
genes other than Ccnd1 all contribute to the proliferation defects observed in 
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complete or conditional mutants of Insm1. In our present study, we used 
Insm1+/lacZ mice, which have mild defects in blood glucose and insulin levels. 
We found that Insm1  regulates Ccnd1 expression and cell cycle length in a 
dose dependent manner.  
 
Zhang and Lan showed that the Insm1 protein can interact with Ccnd1 and 
Ckd4 [36]. Ectopic expression of Insm1 interrupts Ccnd1-Cdk4 function and 
negatively regulates the cell cycle [36, 37]. In Zhang and Lan’s work, they 
defined Insm1 function in nonpancreatic beta cells. Interestingly, abnormally 
high Insm1 expression levels were observed in neuroendocrine tumors, 
including insulinoma cells, which are highly proliferative [38-45]. Tissue 
specific factors can play distinct roles in cell cycle control in different cell 
types, and one dramatic example is provided by the transcription factor RE1 
silencing transcription factor (REST) [46]. Additional investigation is required 
to determine whether Insm1 performs similar or different functions in 
regulating the Ccnd1-Cdk4 complex and cell cycle in pancreatic beta cells 
using additional Insm1 mutant models. 
 
We detected increased apoptosis in pancreatic beta cells from Insm1+/lacZ 
mice. Neurod1 and Pdx1 regulate beta-cell apoptosis in prenatal or aging 
mice [47,48]. Insm1 can bind the Neurod1 promoter and can also regulate the 
expression of Pdx1 [49, 21]. However, our current study showed that Insm1 
dosage does not regulate the expression of these genes, illustrating a 
difference between haploinsufficiency and complete loss of function 
mutations. Furthermore, we did not find an association between delayed cell 
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cycle and apoptosis in Insm1+/lacZ beta cells. Thus, the increase in apoptosis 
in beta cells of Insm1+/lacZ mice is likely independent of the observed cell cycle 
delay and requires further investigation. 
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Figure 1. Decreased Insm1 level in Insm1+/lacZ mice results in low beta-
cell mass and impaired blood glucose levels 
(A) Western blot analysis of Insm1 and Pdx1 protein levels in pancreatic islets 
of 2-month-old wild-type and Insm1+/lacZ mice (left). Quantification of the 
Western blot (right). n=4 for each genotype. (B) Fasted and randomly fed 
blood glucose levels of 2-month-old wild-type and Insm1+/lacZ mice (n=8 for 
each genotype). (C) Glucose tolerance test of 2-month-old wild-type and 
Insm1+/lacZ mice. The area under the curves are 342.88±92.54 mg.h/dl and 
458.53±90.74 mg.h/dl for wild-type and Insm1+/lacZ mice, respectively, with an 
increase of 115.65 mg.h/dl in Insm1+/lacZ mice compared to wild-type animals 
(n=11 for Insm1+/+ and n=10 for Insm1+/lacZ; two-tailed unpaired Student's t-
test, P=0.012). (D) Glucose-stimulated insulin secretion of 2-month-old wild-
type and Insm1+/lacZ mice (n=8 for each genotype). (E) Fasted and randomly 
fed blood glucagon levels of 2-month-old wild-type and Insm1+/lacZ mice (n=5 
for each genotype). (F) Insulin tolerance test of 2-month-old wild-type and 
Insm1+/lacZ mice (n=6 for each genotype). (G) Insulin secretion response to 
low (3.3 mM) and high (16.7 mM) glucose in isolated 2-month-old wild-type 
and Insm1+/lacZ islets (n=4 for each genotype). (H) Pancreatic beta-cell mass 
analyzed in 2-day, 7-day, 14-day, 2-month and 13-month-old wild-type and 
Insm1+/lacZ mice (n=6 for each genotype at each stage). Data are presented 
as the mean ± SD; statistical significance was assessed by a two-tailed 
unpaired Student's t-test. ns: P>0.05, *P < 0.05, **P< 0.01, ***P<0.001. 
 
Figure 2. Prolonged cell cycle in pancreatic beta cells of Insm1+/lacZ mice 
(A) TUNEL analysis indicates apoptosis in pancreatic beta cells at postnatal 
days 2, 7 and 14 in wild-type and Insm1+/lacZ mice (n=5 animals per genotype 
per stage, 4000 insulin+ cells per animal were counted). (B) Ki67 proliferation 
analysis in pancreatic beta cells at postnatal days 2, 7 and 14 in wild-type and 
Insm1+/lacZ mice (n=5 per genotype per stage). (C) Illustration of the 
experimental strategy and the delayed cell cycle detected by BrdU and Ki67 
double labeling. BrdU was injected once, followed by a 23 h chase. The 
BrdU+Ki67- cells have finished the cell cycle during the 23 h chase period, and 
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the BrdU+Ki67+ cells indicate cells still in the cell cycle. The average cell cycle 
time for beta cells is approximately 23 h. The difference in the number of 
BrdU+Ki67- and BrdU+Ki67+ in wild-type and Insm1+/lacZ beta cells indicates a 
difference in the relative time needed to finish one cycle of cell division. (D) 
Immunostaining of insulin, Ki67 and BrdU in the pancreas of wild-type and 
Insm1+/lacZ mice at P14. Red arrows indicate BrdU+Ki67- beta cells (E). 
Quantification of the immunostaining showed in (D) for BrdU+Ki67- and 
BrdU+Ki67+ beta-cell (600 BrdU+ cells were counted from 4-6 sections per 
animal, 5 animals per genotype). Data are presented as the mean ± SD; 
statistical significance was assessed by a two-tailed unpaired Student's t-test. 
*P < 0.05.
Figure 3. Ccnd1 is downregulated in islets of Insm1+/lacZ mice and Ccnd1 
levels regulate cell cycle length 
(A) PI staining and flow cytometry analysis of cell cycle (n=4, two-tailed
unpaired Student's t-test compared to siCon: P=0.033 (siInsm1), P=0.012 
(siCcnd1), P=0.13 (siInsm1+Ccnd1 plasmid)). (B) Expression of cell cycle 
genes in islets of 14-day-old wild-type and Insm1+/lacZ mice (n=5 for each 
genotype). (C) Ccnd1 protein levels in islets isolated from 14-day-old wild-type 
and Insm1+/lacZ mice (n=4). (D) Analysis of cell cycle length by BrdU and Ki67 
double labeling in control, knockdown of Insm1, Ccnd1 and Insm1 knockdown 
combined with overexpression of Ccnd1 in SJb cells (n=4). (B, C, D) Data are 
presented as the mean ± SD; statistical significance was assessed by a two-
tailed unpaired Student's t-test.  *P < 0.05. 
Figure 4. Glut2 expression is downregulated in islets of Insm1+/lacZ mice 
(A) Expression of metabolic genes and transcription factors in islets of 14-day-
old wild-type and Insm1+/lacZ mice (n=5 for each genotype). (B) Glut2 and 
Neurod1 protein levels in islets isolated from 14-day-old wild-type and 
Insm1+/lacZ mice. Left, representative blot; right, quantifications (n=4 for each 
genotype). Data are presented as the mean ± SD; statistical significance was 
assessed by a two-tailed unpaired Student's t-test.  *P < 0.05, **P < 0.01. 
Figure 5. Dosage effects and binding affinities of Insm1 
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(A) ChIP-seq traces of Insm1 binding sites and the reads on Ccnd1, Pdx1, 
Hk1 and Slc2a2 (Glut2) loci in SJb cells. (B, left) Insm1 protein levels in 
control and Insm1 siRNA transfected SJb cells detected by Western blot. Top 
panel shows the representative blot, bottom panel indicates the quantification 
(n=4). (B, right) ChIP using an Insm1 antibody in control and Insm1 
knockdown SJb cells, qPCR showing the relative amount of Insm1 binding to 
the indicated loci in control and Insm1 siRNA transfected cells. Fold change of 
binding (sicon vs siInsm1) on the individual gene loci: Ccnd1-pro 8.8, 
Ccnd1_intron 10.3, Pdx1 1.7, Hk1 1.4, Glut2 5.7, Gapdh 0.5 (n=4). (C) ChIP-
PCR from islets of 14-day-old wild-type and Insm1+/lacZ mice (n=4). Data are 
presented as the mean ± SD. Two-tailed unpaired Student's t-test, ns: 
P>0.05, *P < 0.05, **P<0.01, ***P<0.001 
 
Figure 6. The ratio of beta-cell mass between wild-type and Insm1+/lacZ 
mice is maintained during metabolic stress  
(A,B,C) Glucose tolerance test in wild-type and Insm1+/lacZ mice on an ob/ob 
background (A), treated with normal chow (NC) (B) or a high-fat diet (HFD) 
(C). The area under the curves for wild-type and Insm1+/lacZ mice are 
367.82±148.12 mg.h/dl and 595.48±86.44 mg.h/dl (n=8, two-tailed unpaired 
Student's t-test, P=0.0035) (A), 208.63±52.65 mg.h/dl and 346.47±14.16 
mg.h/dl (n=6, two-tailed unpaired Student's t-test, P=0.0076) (B), 
309.14±62.81 mg.h/dl and 675.28±155.91 mg.h/dl (n=8, two-tailed unpaired 
Student's t-test, P= 0.000055) (C), respectively, with the enlargement of 
227.66 mg.h/dl (A), 137.84 mg.h/dl (B) and 366.15 mg.h/dl (C) in Insm1+/lacZ 
mice (0.5 g/kg glucose per bodyweight was used for ob/ob mice and 2 g/kg 
used for NC and HFD mice). Blood glucose tests from fasted (D) and 
randomly fed (E) wild-type and Insm1+/lacZ mice on a HFD or ob/ob 
background (n=8 for Insm1+/+ and n=12 for Insm1+/lacZ). (F) Analysis of beta-
cell mass in wild-type and Insm1+/lacZ animals on a HFD or ob/ob background 
(n=6). (G) Relative gene expression in 13-month-old wild-type and Insm1+/lacZ 
mice (n=3). (H) ChIP-PCR from islets of 13-month-old Insm1+/+ and Insm1+/lacZ 
mice (n=4). Data are presented as the mean ± SD; statistical significance was 
assessed by a two-tailed unpaired Student's t-test. ns: P>0.05, *P < 0.05, **P 
< 0.01, ***P<0.001. 
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Figure S1.  Insm1 expression levels in islets of Insm1+/lacZ mice 
Insm1 expression levels in P14 islets of Insm1+/+ and Insm1+/lacZ mice 
detected by Western blot (left); Quantification of the expression levels (right, 
n=4). Data are presented as means ± SD. Statistical significance was 
assessed by 2-tailed unpaired Student's t-test.  *: P<0.05 
Figure S2.  Proportions of endocrine cells in in islets of Insm1+/lacZ mice 
Immunostaining of Insm1, DAPI and endocrine cell markers Gcg / Pp / Sst / 
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of the islets endocrine cell types, 400 cells for Gcg/Pp/Sst positive cells and 
2000 cells for Ins positive cells were counted. (Animal number n=4 for each 
genotype). Data are presented as means ± SD. Statistical significance was 
assessed by 2-tailed unpaired Student's t-test.  ns: P>0.05. 
Figure S3. Pancreatic beta cell size of Insm1+/+ and Insm1+/lacZ mice 
Staining of Insulin, beta-catenin and DAPI in pancreas of Insm1+/+ and 
Insm1
+/lacZ mice at the age of 2-month (left), quantification of beta cell size by 
measuring insulin positive area and counting of DAPI number in Insulin 
positive cells (right). (Counting 2000 cell per animal, Animal number n=6). 
Data are presented as means ± SD. Statistical significance was assessed by 
2-tailed unpaired Student's t-test.  ns: P>0.05.
Figure S4. Cell cycle length and Ccnd1 expression in islets of Insm1+/lacZ 
mice 
(A) Quantification of BrdU+Ki67- and BrdU+Ki67+ beta cells (600 BrdU+ cells
per animal and 4 animals per genotypes) in islets of Insm1+/+ and Insm1+/lacZ
mice at the ages of 3-week and 10-week. (B) Expression of cell cycle genes in
non-target siRNA and Insm1 specific siRNA treated SJb cells (n=4 for each
cell treatment). (C) The mRNA levels of Ccnd1 in islets of postnatal 7-day and
3-month old animals (animal number n=3 for each genotype). Data are
presented as means ± SD. Statistical significance was assessed by 2-tailed 
unpaired Student's t-test, *: P < 0.05. 
Figure S5. Indicated genes expression under Insm1-dosage deficiency 
(A) Protein levels of CcnE1, CcnA2, p16, p21, p27 and p57 in P14 islets of
Insm1
+/+ and Insm1+/lacZ mice (n=4). (B) NeuroD1 mRNA level in P42 islets 
detected by qRT-PCR (n=4). (C) No Insm1 binding on Cdkn1c locus. Up 
trace, Insm1 ChIP-seq; low trace, IgG ChIP-seq trace. IgG ChIP-seq trace 
was used as non-binding control. Data are presented as means ± SD. 
Statistical significance was assessed by 2-tailed unpaired Student's t-test, ns: 
P>0.05.
Figure S6. The area under the curves (AUCs) analysis of GTT related to 
Fig.1 and Fig. 6 
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(A) AUC of GTT on 2-month old Insm1+/+ and Insm1+/lacZ mice (n=11 for
Insm1+/+ and n=10 for Insm1+/lacZ). (B) AUC of GTT on 1-year old Insm1+/+ and
Insm1+/lacZ mice treated with NC (n=6). (C) AUC of GTT on an ob/ob
background Insm1+/+ and Insm1+/lacZ mice (n=8). (D) AUC of GTT on Insm1+/+
and Insm1+/lacZ mice treated with HFD (n=8). Two-tailed unpaired Student's t-
test, *P < 0.05, **P<0.01, ***P<0.001.
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